Indium (111in) Chloride Curium Netherlands (Indium (111in) Chloride)

Indium-111 chloride emits gamma radiation that can be captured by a gamma camera. After intravenous injection, it binds to white blood cells or accumulates in bone marrow and tumor tissue, allowing the emitted photons to be visualized and providing functional images of physiological and pathological processes.

The administered activity of Indium (111in) Chloride is determined by the prescribing physician based on the specific diagnostic indication, patient weight, and imaging protocol. Dosage is individualized and should follow the radiopharmacy’s preparation guidelines and regulatory requirements.

The safety of Indium (111in) Chloride in pregnancy and lactation has not been established. Use is generally avoided unless the diagnostic benefit outweighs potential risks. If administered, appropriate counseling and monitoring are recommended, and breastfeeding may need to be paused for a defined period.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Indium (111in) Chloride is a well‑established leukocyte labeling agent offering high specificity for infection and inflammation. Compared with newer agents such as 99mTc‑labeled compounds, it provides longer imaging windows due to its 2.8‑day half‑life, but requires more complex preparation and handling of radioactive material.

The product should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. It should be kept in its original container until use, and handled by trained personnel using appropriate radiation safety measures.

Indium (111in) Chloride is supplied as an injectable solution for intravenous administration. The preparation is typically performed by a radiopharmacy, where the tracer is labeled to leukocytes or prepared for direct injection, followed by imaging at predetermined time points.

Serious risks include severe allergic reactions or anaphylaxis, significant hypotension, radiation‑induced tissue injury, and hematologic abnormalities such as leukopenia. Prompt recognition and management of these events are essential, and patients should be monitored during and after administration.

Patients with known hypersensitivity to indium compounds, those who are pregnant unless absolutely necessary, and individuals with severe renal impairment or uncontrolled cardiovascular instability should generally avoid this tracer. Clinical judgment is required to assess suitability on a case‑by‑case basis.